Shares of Vertex Pharmaceuticals have received an average “Moderate Buy” rating from 26 brokerages. Analysts are divided, ...

TD Cowen analyst Phil Nadeau maintained a Hold rating on Xoma (XOMA – Research Report) yesterday. The company’s shares closed yesterday at ...

This was the stock's fourth consecutive day of gains.

In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

After you've had surgery or experienced a serious physical injury, you are more than likely going to be in a lot of pain. No matter what your pain tolerance is, recovering from surgery or any ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.